Literature DB >> 7539763

Purification and characterization of endogenous peptides extracted from HLA-DR isolated from the spleen of a patient with rheumatoid arthritis.

R D Gordon1, J A Young, S Rayner, R W Luke, M L Crowther, P Wordsworth, J Bell, G Hassall, J Evans, S A Hinchliffe.   

Abstract

We have purified HLA-DR from the spleen of a patient with rheumatoid arthritis. The patient had Felty's syndrome and was heterozygous for the DR4Dw4 antigen. We have isolated endogenous peptides from purified HLA-DR molecules. The peptides were purified by reverse phase HPLC and the major peaks were subjected to N-terminal sequencing. The peptides were derived from a variety of proteins: human serum albumin, human erythroid protein 4.1, 60S ribosomal proteins L31 and L35, VCAM-1, human immunoglobulin lambda chain and cathepsin-S. A peptide corresponding to the sequence of human serum albumin (HSA) residues 106-120 was synthesized and shown to bind to HLA-DR4Dw4 (IC50 = 1.41 microM). We have confirmed and refined current ideas about the structural motif for the binding of peptides to HLA-DR and HLA-DR4Dw4.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539763     DOI: 10.1002/eji.1830250553

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Presentation of a cytosolic antigen by major histocompatibility complex class II molecules requires a long-lived form of the antigen.

Authors:  M Guéguen; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

2.  Peptides presented by HLA-DR molecules in synovia of patients with rheumatoid arthritis or antibiotic-refractory Lyme arthritis.

Authors:  Robert J Seward; Elise E Drouin; Allen C Steere; Catherine E Costello
Journal:  Mol Cell Proteomics       Date:  2010-11-16       Impact factor: 5.911

3.  Immunogenic HLA-DR-Presented Self-Peptides Identified Directly from Clinical Samples of Synovial Tissue, Synovial Fluid, or Peripheral Blood in Patients with Rheumatoid Arthritis or Lyme Arthritis.

Authors:  Qi Wang; Elise E Drouin; Chunxiang Yao; Jiyang Zhang; Yu Huang; Deborah R Leon; Allen C Steere; Catherine E Costello
Journal:  J Proteome Res       Date:  2016-11-07       Impact factor: 4.466

4.  Approach for Identifying Human Leukocyte Antigen (HLA)-DR Bound Peptides from Scarce Clinical Samples.

Authors:  Tina Heyder; Maxie Kohler; Nataliya K Tarasova; Sabrina Haag; Dorothea Rutishauser; Natalia V Rivera; Charlotta Sandin; Sohel Mia; Vivianne Malmström; Åsa M Wheelock; Jan Wahlström; Rikard Holmdahl; Anders Eklund; Roman A Zubarev; Johan Grunewald; A Jimmy Ytterberg
Journal:  Mol Cell Proteomics       Date:  2016-07-24       Impact factor: 5.911

5.  A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease.

Authors:  Elise E Drouin; Robert J Seward; Klemen Strle; Gail McHugh; Kianoosh Katchar; Diana Londoño; Chunxiang Yao; Catherine E Costello; Allen C Steere
Journal:  Arthritis Rheum       Date:  2013-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.